{"id":"W2999930180","doi":"10.1016/s0923-7534(20)34327-1","title":"Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Temsirolimus; Sunitinib; Sorafenib; Renal cell carcinoma; Internal medicine; Clinical endpoint; Progression-free survival; Oncology; Gastroenterology; Urology; Surgery; Randomized controlled trial; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001533533,0.0015006,0.002649242,0.0003176814,0.0002600634,0.001090577,0.0006054175,0.0008559313,0.003026556],"category_scores_gemma":[0.001411762,0.0003187322,0.002930016,0.0004017155,0.0006654641,0.00121273,0.0004274171,0.002833408,0.0005754395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009725184,"about_ca_system_score_gemma":0.000857075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001079711,"about_ca_topic_score_gemma":0.003277824,"domain_scores_codex":[0.9994966,0.0002476261,0.00003194497,0.00008706645,0.00005086257,0.00008589574],"domain_scores_gemma":[0.9994208,0.0001469546,0.0001396371,0.00005235798,0.00003430931,0.0002060493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9315395,0.002426897,0.002803416,0.001239895,0.004265752,0.000129305,0.000106635,0.00219343,0.004456389,0.000388486,0.003872067,0.04657819],"study_design_scores_gemma":[0.8335108,0.1210156,0.02445642,0.0001904242,0.007981483,0.0004615448,0.0001752389,0.002829271,0.002634765,0.001192251,0.005463761,0.00008837746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867964,0.007534035,0.0003176974,0.000958635,0.0003370695,0.0002490151,0.001173561,0.00008203625,0.002551607],"genre_scores_gemma":[0.9895509,0.003390288,0.0005721209,0.0008483361,0.0003094029,0.0002792427,0.002237783,0.00003535877,0.002776557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003026556,"threshold_uncertainty_score":0.0101248,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1424243456853607,"score_gpt":0.3746924568130888,"score_spread":0.2322681111277281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}